Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fujifilm, Mitsubishi in Bio-CMO Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fujifilm, Mitsubishi in Bio-CMO Pact

Mitsubishi to gain 20% equity in new bio-CMO network, add global sales and marketing

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Fujifilm and Mitsubishi have entered into a partnership in for biopharma contract manufacturing. The companies have signed an agreement to transfer the ownership of 20% equity interests in Fujifilm’s wholly-owned biopharmaceutical contract manufacturing subsidiaries, Fujifilm Diosynth Biotechnologies U.S.A. Inc. (FDBUS) and FUJIFILM Diosynth Biotechnologies UK Limited (FDBUK), to Mitsubishi Corporation. Mitsubishi Corporation will become involved in the business management of FDBUS and FDBUK alongside Fujifilm in a joint effort to strongly promote the expansion of the bio-CMO business.

Fujifilm established FDBUS and FDBUK after acquiring the Merck Biomanufacturing Network from Merck earlier this year. According to a joint corporate statement, “Mitsubishi Corporation is tapping into its extensive experiences in the pharmaceutical business, including biopharmaceuticals, as it becomes involved in the management of FDBUS and FDBUK. It will make use of its global sales network and marketing capability, thereby contributing to strengthening the companies’ sales capacity in areas such as attracting new customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics